An adenovirus recombinant expressing the spike glycoprotein of porcine respiratory coronavirus is immunogenic in swine

Callebaut, P.; Enjuanes, Luis; Pensaert, Maurice

doi:10.1099/0022-1317-77-2-309

Cited by 28 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The spike (S) glycoprotein of CoVs is known to be the major inducer of virus‐neutralizing antibodies responsible for protective antiviral immunity (Callebaut et al ., ; Torres et al ., ). Furthermore, the truncated version of the SARS‐CoV S protein (S1) has been shown to contain important antigenic domains (Babcock et al ., ).…”

Section: Advances In the Development Of Plant‐based Subunit Vaccinesmentioning

confidence: 98%

Plant‐produced candidate countermeasures against emerging and reemerging infections and bioterror agents

Streatfield

Kushnir

Yusibov

2015

Plant Biotechnology Journal

View full text Add to dashboard Cite

Keywords: emerging and reemerging infections, bioterrorism, plant-produced recombinant protein, subunit vaccine, virus-like particle, monoclonal antibody. SummaryDespite progress in the prevention and treatment of infectious diseases, they continue to present a major threat to public health. The frequency of emerging and reemerging infections and the risk of bioterrorism warrant significant efforts towards the development of prophylactic and therapeutic countermeasures. Vaccines are the mainstay of infectious disease prophylaxis. Traditional vaccines, however, are failing to satisfy the global demand because of limited scalability of production systems, long production timelines and product safety concerns. Subunit vaccines are a highly promising alternative to traditional vaccines. Subunit vaccines, as well as monoclonal antibodies and other therapeutic proteins, can be produced in heterologous expression systems based on bacteria, yeast, insect cells or mammalian cells, in shorter times and at higher quantities, and are efficacious and safe. However, current recombinant systems have certain limitations associated with production capacity and cost. Plants are emerging as a promising platform for recombinant protein production due to time and cost efficiency, scalability, lack of harboured mammalian pathogens and possession of the machinery for eukaryotic post-translational protein modification. So far, a variety of subunit vaccines, monoclonal antibodies and therapeutic proteins (antivirals) have been produced in plants as candidate countermeasures against emerging, reemerging and bioterrorism-related infections. Many of these have been extensively evaluated in animal models and some have shown safety and immunogenicity in clinical trials. Here, we overview ongoing efforts to producing such plant-based countermeasures.

show abstract

Section: Advances In the Development Of Plant‐based Subunit Vaccinesmentioning

confidence: 98%

Plant‐produced candidate countermeasures against emerging and reemerging infections and bioterror agents

Streatfield

Kushnir

Yusibov

2015

Plant Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…Efforts to develop a vaccine against SARS are necessarily based on only the limited knowledge gained from studies of SARS-CoV, as well as on anti-CoV strategies that have been devised over the years. Several groups have shown that the spike glycoproteins are major inducers of neutralizing antibodies, providing protective immunity against many CoVs (7)(8)(9)(10)(11). Currently, the SARS-CoV S glycoprotein and its truncated versions are considered the best candidates for generation of a recombinant vaccine against this disease (12)(13)(14)(15)(16)(17)(18)(19)(20).…”

mentioning

confidence: 99%

Severe acute respiratory syndrome (SARS) S protein production in plants: Development of recombinant vaccine

Pogrebnyak

Golovkin

Andrianov

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

121

View full text Add to dashboard Cite

In view of a recent spread of severe acute respiratory syndrome (SARS), there is a high demand for production of a vaccine to prevent this disease. Recent studies indicate that SARS-coronavirus (CoV) spike protein (S protein) and its truncated fragments are considered the best candidates for generation of the recombinant vaccine. Toward the development of a safe, effective, and inexpensive vaccine candidate, we have expressed the N-terminal fragment of SARS-CoV S protein (S1) in tomato and low-nicotine tobacco plants. Incorporation of the S1 fragment into plant genomes as well as its transcription was confirmed by PCR and RT-PCR analyses. High levels of expression of recombinant S1 protein were observed in several transgenic lines by Western blot analysis using specific antibodies. Plant-derived antigen was evaluated to induce the systemic and mucosal immune responses in mice. Mice showed significantly increased levels of SARS-CoV-specific IgA after oral ingestion of tomato fruits expressing S1 protein. Sera of mice parenterally primed with tobacco-derived S1 protein revealed the presence of SARS-CoV-specific IgG as detected by Western blot and ELISA analysis.immune response ͉ plant biotechnology ͉ severe acute respiratory syndrome-coronavirus ͉ recombinant subunit vaccine T he recent spread of severe acute respiratory syndrome (SARS) has heightened demand for a SARS vaccine that is safe, effective, economical, and easily administered. The production of recombinant subunit vaccines has become a valuable modern strategy for prevention of infectious diseases (1, 2). Development of such vaccines relies on the identification of the best antigen and the choice of expression system. The causative agent of SARS has been identified as SARScoronavirus (CoV) (3-5), which is similar to other CoVs in both virion structure and genomic organization (5, 6). Efforts to develop a vaccine against SARS are necessarily based on only the limited knowledge gained from studies of SARS-CoV, as well as on anti-CoV strategies that have been devised over the years. Several groups have shown that the spike glycoproteins are major inducers of neutralizing antibodies, providing protective immunity against many CoVs (7-11). Currently, the SARS-CoV S glycoprotein and its truncated versions are considered the best candidates for generation of a recombinant vaccine against this disease (12)(13)(14)(15)(16)(17)(18)(19)(20). The full-length SARS-CoV spike protein (S protein) is large (139 kDa) and probably not cleaved into S1 and S2 subunits (21,22). The N-terminal part of the SARS-CoV S protein (S1) contains a putative receptor-binding domain (RBD) that is responsible for cell attachment (15,23). Antibodies against this region were found to be highly effective in blocking RBD-receptor interaction in other CoVs (24). Moreover, vaccinated animals developed an antibody response against the S1 fragment of SARS S protein (25), and SARS patient sera showed significant immunoreactivity with peptide located within the S1 region (19).Recent studies have s...

show abstract

“…In this report, we investigated the potential of intranasal immunization with recombinant BAV-3 for inducing protective immune responses against BHV-1 challenge. While animal studies using recombinant human adenoviruses have been reported (Callebaut et al, 1996 ;Mittal et al, 1996 ;Prevec et al, 1989), the present study differs in two aspects. First, the experiment was done in calves, the natural host of BAV-3.…”

Section: Discussionmentioning

confidence: 44%

“…Although recombinant human adenoviruses have been shown to be effective vectors for the delivery of vaccine antigens to animals (Callebaut et al, 1996 ;Prevec et al, 1989 ;Torres et al, 1996), their use as a vaccine-delivery system in domestic animals is limited in part due to safety concerns. As non-human adenoviruses are species specific, the development of animal-specific adenovirus would be a logical choice.…”

Section: Discussionmentioning

confidence: 99%

Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1.

Zakhartchouk¹,

Pyne²,

Mutwiri³

et al. 1999

Journal of General Virology

View full text Add to dashboard Cite

An adenovirus recombinant expressing the spike glycoprotein of porcine respiratory coronavirus is immunogenic in swine

Abstract: The full-length spike (S) gene of porcine respiratory coronavirus (PRCV) was inserted into the genome of human adenovirus type 5 downstream of the early transcription region 3 promoter. The recombinant virus replicated in cultures of the swine testicle ST

Cited by 28 publications

References 18 publications

Plant‐produced candidate countermeasures against emerging and reemerging infections and bioterror agents

Plant‐produced candidate countermeasures against emerging and reemerging infections and bioterror agents

Severe acute respiratory syndrome (SARS) S protein production in plants: Development of recombinant vaccine

Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1.

Contact Info

Product

Resources

About